IMMUTEP Aktie

>IMMUTEP Aktienkurs

0.031 EUR +10.7% (TradegateBSX)

Ask: 0.032 EUR / 5500 Stück

Bid: 0.03 EUR / 70000 Stück

Tagesumsatz: 100000 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

IMMUTEP Aktie über LYNX handeln

Intraday

1 Jahr

>IMMUTEP Performance

1 Woche: -11,4%

1 Monat: -86,0%

3 Monate: -87,3%

6 Monate: -80,1%

1 Jahr: -79,1%

laufendes Jahr: -86,8%

>IMMUTEP Aktie

Name:

IMMUTEP LTD

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000IMM6 / A2H81H

Symbol/ Ticker:

YP1B (Frankfurt)

Kürzel:

FRA:YP1B, ETR:YP1B, YP1B:GR

Index:

Webseite:

https://www.immutep.com/

Profil:

Immutep Limited is a late-stage biotechnology company specializing in the development of innovative immunotherapies for cancer and autoimmune diseases. Headquartered in Sydney, Australia, with operations spanning Europe and the United States, Immutep..
>Volltext..

Marktkapitalisierung:

40.54 Mio. EUR

Unternehmenswert:

-15.06 Mio. EUR

Umsatz:

2.36 Mio. EUR

EBITDA:

-49.85 Mio. EUR

Nettogewinn:

-48.51 Mio. EUR

Gewinn je Aktie:

-0.03 EUR

Schulden:

0.7 Mio. EUR

Liquide Mittel:

42.05 Mio. EUR

Operativer Cashflow:

-35.93 Mio. EUR

Bargeldquote:

2.11

Umsatzwachstum:

Gewinnwachstum:

-81.86%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

IMMUTEP

Letzte Datenerhebung:

04.04.26

>IMMUTEP Kennzahlen

Aktien/ Unternehmen:

Aktien: 1473.72 Mio. St.

Frei handelbar: 97.08%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Neutral

Kursziel: 926.27%

Bewertung:

KGV: -

KGV lG: -

KUV: 19.88

KBV: 0.84

PEG-Ratio: -0.01

EV/EBITDA: -

Rentabilität:

Bruttomarge: 45.35%

Gewinnmarge: -2056.63%

Operative Marge: -2168.05%

Managementeffizenz:

Gesamtkaprendite: -50.93%

Eigenkaprendite: -61.85%

>IMMUTEP Peer Group

Gesundheit, Antikörper- Behandlung, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>IMMUTEP Chart & Kurs - Tradegate

>IMMUTEP News

04.04.26 - 18:09	Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
	NEW YORK, April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep Ltd. may have issued materially misleading......

02.04.26 - 16:07	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP (PR Newswire)
	NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Immutep Limited ("Immutep" or the "Company") (NASDAQ: IMMP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation......

24.03.26 - 06:12	Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
	NEW YORK, March 24, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially......

20.03.26 - 07:30	ASX Runners of the Week: Immutep, Blue Star Helium & Patagonia (SMH)
	The Bulls N' Bears ASX Runner of the Week is… Immutep. The oncology mid-cap bounced hard from last week's 90 per cent drop, gaining 53 per cent after a brutal sell-off....

20.03.26 - 02:30	HotList stocks: Northern Star, Immutep, Lodestar, and other trending companies in Week 12 (Market Herald)
	Good afternoon, and welcome to the HotCopper HotList column. Every week, ASX…...

19.03.26 - 04:30	Thursday’s HotCopper trends: Racura, EVR, Immutep, and other daily topics \| March 19 (Market Herald)
	Racura is well out in front on the Australian bourse topic-wise today…...

18.03.26 - 22:31	IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Trial Progress: Levi & Korsinsky (PR Newswire)
	Immutep Reported TACTI-004 Futility Analysis Was "On Track" in January 2026 -- Weeks Later the Trial Was Halted After Failing to Meet Efficacy Endpoints NEW YORK, March 18, 2026 /PRNewswire/ -- Shareholders of Immutep Ltd. (NASDAQ: IMMP) who lost money are urged to act now. On January 30,......

18.03.26 - 20:03	Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP (PR Newswire)
	NEW YORK, March 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Immutep Ltd. (NASDAQ: IMMP) resulting from allegations that Immutep may have issued materially......

13.03.26 - 13:18	Immutep-Aktie stürzt nach Abbruch von Lungenkrebsstudie um 80 % ab (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.03.26 - 12:00	Immutep halts late-stage trial for lead asset after efficacy analysis (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.03.26 - 08:25	XFRA: YP1B: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN IMMUTEP LTD YP1B AU000000IMM6 AB/FROM ONWARDS 13.03.2026...

13.03.26 - 05:00	HotCopper Highlights Week 11: Immutep scalped; Syrah Trump’s latest victim; Japan’s Lynas handout & more (Market Herald)
	Good Afternoon, I'm Jon Davidson, it's a Friday and you know what…...

13.03.26 - 04:00	The ides of March come for Immutep as lung cancer trial cancellation triggers plummet (Market Herald)
	Immutep Ltd (ASX:IMM) has seen its share price slaughtered on Friday after…...

13.03.26 - 03:36	Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today (Fool)
	These shares are ending the week in the red? Here's why. The post Why CAR Group, Immutep, Northern Star, and Syrah Resources shares are sinking today appeared first on The Motley Fool Australia....

13.03.26 - 03:12	Hedge Fund Regal Hit by 93% Crash in Australian Biotech Stock (Bloomberg)
	Sydney hedge fund Regal Partners Ltd. was dealt a fresh blow after Immutep Ltd., an Australian biotech company it backs, wiped out most of its A$582 million ($412 million) market value on Friday when it halted trials of a lung cancer drug....

13.03.26 - 02:36	Immutep Discontinues TACTI-004 Phase III Trial Due to Futility (Small Caps)
	Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027....

09.03.26 - 02:48	Why the Immutep share price is halted today (Fool)
	Immutep shares are frozen as investors await a major trial update. The post Why the Immutep share price is halted today appeared first on The Motley Fool Australia....

06.03.26 - 08:13	XFRA: INSTRUMENT_SUSPENSION - AU000000IMM6 (XETRA)
	Instrument ID [1450] (YP1B - AU000000IMM6) suspended...

06.03.26 - 08:13	XFRA: YP1B: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL IMMUTEP LTD YP1B AU000000IMM6 BAW/UFN...

06.02.26 - 14:03

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (GlobeNewswire EN)

SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as first line therapy for advanced/metastatic non-small cell lung cancer (1L NSCLC)....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram